Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007–2013

Zhang, Dongmu; Johnson, Kelly; Newransky, Chrisann; Acosta, Camilo J.

doi:10.1016/j.amepre.2016.08.029

Cited by 24 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This assumption was based on other vaccine coverage in adults in Germany and also on a comparison of coverage rates for ZVL in the US and UK. 22 Coverage rates in the US have been reported to be 23.9% of adults aged 60–64 years, and 14.5% in adults aged 65+ years 23 whereas in the UK they have varied between 54.9% and 61.8% in the routine cohort aged 70 y. 24 As no herd effect is assumed, the results presented here can be easily modified to reflect other coverage rates.…”

Section: Discussionmentioning

confidence: 91%

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

Curran

Oorschot

Varghese³

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The aim of this study was to compare the public health impact of introducing 2 Herpes Zoster (HZ) vaccines, Zoster Vaccine Live (ZVL) versus a non-live adjuvanted subunit candidate vaccine (HZ/su), in the German population aged 50+ years split into 3 age cohorts, i.e. 50–59, 60–69 and 70+ years, respectively. A multi-cohort static Markov model was developed following age cohorts over their lifetime. Demographic data were obtained from the German federal statistical office. HZ incidence and the proportion of HZ individuals developing post-herpetic neuralgia (PHN) were derived from German specific sources. Age-specific vaccine efficacy and waning rates were based on published clinical trial data. Vaccine coverage for both vaccines was assumed to be 40%, with compliance of the second dose of the HZ/su vaccine of 70%. Sensitivity analyses were performed to assess the robustness of the results. It was estimated that, over the remaining lifetime since vaccination, the HZ/su vaccine would reduce the number of HZ cases by 725,233, 533,162 and 486,794 in the 3 age cohorts, respectively, compared with 198,477, 196,000 and 104,640, using ZVL. The number needed to vaccinate (NNV) to prevent one HZ case ranged from 8 to 11 using the HZ/su vaccine compared with 20 to 50 using ZVL. Corresponding NNV to prevent one PHN case ranged from 39 to 53 using the HZ/su vaccine compared with 94 to 198 using ZVL. Due to the higher, sustained vaccine efficacy, the candidate HZ/su vaccine demonstrated superior public health impact compared with ZVL.

show abstract

Section: Discussionmentioning

confidence: 91%

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

Curran

Oorschot

Varghese³

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…The vaccination coverage was assumed to be 40%, based on the observed coverage for a pneumococcal polysaccharide vaccine for older adults recently licensed in Japan. Coverage rates for ZVL observed in the USA and UK have ranged between 14.5% in individuals aged ≥ 65 years in the USA [ 37 ] and 61.8% in individuals aged ≥ 70 years in the UK [ 38 ]. Varying the assumed vaccination coverage has a large impact on the estimate of the differences in the number of HZ cases avoided by using RZV rather than VVL, ranging from approximately 1.3 million cases avoided with a 20% coverage rate to 3.8 million with a 60% coverage rate.…”

Section: Discussionmentioning

confidence: 99%

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis

Watanabe

Mizukami

Holl

et al. 2018

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

IntroductionThe aim of this study was to compare the public health impact of introducing two herpes zoster (HZ) vaccines into the vaccination programs for the Japanese population aged ≥ 50 years: a single-dose Varicella Vaccine Live (VVL) or a two-dose adjuvanted Recombinant Zoster Vaccine (RZV).MethodsA multi-cohort static Markov model was developed to follow age cohorts (50–59, 60–69, 70–79 and ≥ 80 years) over their remaining lifetime. Japan-specific data inputs for the model were obtained from Japanese data sources. Age-stratified vaccine efficacy and waning rates were based on published clinical trial data. In the base-case analysis, vaccine coverage was assumed to be 40% for both vaccines, and compliance with second-dose of the RZV vaccine was set to 95%.ResultsVaccination with RZV was projected to prevent approximately 3.3 million HZ cases, 692,000 cases of postherpetic neuralgia (PHN), and 281,000 cases of other complications, compared with the prevention of 0.8 million HZ cases, 216,000 PHN cases, and 57,000 other complications with vaccination with VVL. The number of individuals needed to vaccinate in order to prevent one HZ case ranged from 6 to 14 using RZV (depending on age and assumed second-dose compliance) and from 21 to 138 depending on age using VVL. By preventing a higher number of HZ cases and its complications, RZV vaccination led to fewer outpatient visits and hospitalizations than vaccination with VVL.ConclusionBoth vaccines had a positive public health impact compared to no vaccination, but due to its higher vaccine efficacy, RZV demonstrated a superior public health impact compared with VVL.FundingGlaxoSmithKline Biologicals SA.Electronic supplementary materialThe online version of this article (10.1007/s13555-018-0236-3) contains supplementary material, which is available to authorized users.

show abstract

“…Females, those above 65 years, and non-Hispanic whites were all more likely to be vaccinated for HZ. 63 Also the chances of being vaccinated were directly proportional to the frequency of outpatient hospital/ physician/pharmacy visits and inversely proportional to the number of emergency room and/or inpatient visits. Costs of the vaccine and reimbursement remains one of the top barriers in the uptake of this vaccine.…”

Section: Preventionmentioning

confidence: 99%

“…Costs of the vaccine and reimbursement remains one of the top barriers in the uptake of this vaccine. 58, 63 …”

Section: Preventionmentioning

confidence: 99%

Herpes Zoster in the Older Adult

John

Canaday

2017

Infectious Disease Clinics of North America

113

101

View full text Add to dashboard Cite

Synopsis Herpes Zoster (HZ) is the result of reactivation of latent varicella zoster virus (VZV) and occurs most frequently in older adults. Generally, HZ presents as a unilateral, self-limited dermatomal rash. Postherpetic neuralgia (PHN) is a common sequela; presenting as severe pain that persists after the rash has resolved. It occurs more commonly in older age and can be very debilitating. Management of HZ in the elderly requires a prompt diagnosis, treatment with antivirals, and adequate pain control. A longer- term pain management strategy is required if PHN occurs. A modestly effective vaccine exists and is recommended for older individuals.

show abstract

Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007–2013

Abstract: Estimated HZ vaccine coverage is 19.5% in adults aged ≥60 years, which is lower than the Healthy People 2020 target of 30%. Providers should identify every opportunity for HZ vaccination to assure that older adults are protected from HZ, a vaccine-preventable disease.

Cited by 24 publications

References 21 publications

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis

Herpes Zoster in the Older Adult

Contact Info

Product

Resources

About